2021
Oral anticancer agent (OAA) adherence and survival in elderly patients with metastatic renal cell carcinoma (mRCC).
Dinan M, Wilson L, Greiner M, Spees L, Pritchard J, Zhang T, Kaye D, George D, Scales C, Wheeler S. Oral anticancer agent (OAA) adherence and survival in elderly patients with metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2021, 39: 280-280. DOI: 10.1200/jco.2021.39.6_suppl.280.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaOral anticancer agentsDisease-specific survivalRenal cell carcinomaCell carcinomaPatient populationSEER-Medicare patientsDisease-specific mortalityNumber of comorbiditiesOlder patient populationProgression-free survivalReal-world adherenceRandomized clinical trialsTreatment of patientsAnalysis of patientsProportion of daysRCC-specific mortalityMinimum effective doseSignificant reductionOAA therapyCause mortalityElderly patientsFavorable survivalMetastatic RCCMultivariable analysis
2012
Changes in Initial Treatment for Prostate Cancer Among Medicare Beneficiaries, 1999–2007
Dinan MA, Robinson TJ, Zagar TM, Scales CD, Curtis LH, Reed SD, Lee WR, Schulman KA. Changes in Initial Treatment for Prostate Cancer Among Medicare Beneficiaries, 1999–2007. International Journal Of Radiation Oncology • Biology • Physics 2012, 82: e781-e786. PMID: 22331001, PMCID: PMC3418871, DOI: 10.1016/j.ijrobp.2011.11.024.Peer-Reviewed Original ResearchConceptsAndrogen deprivation therapyThree-dimensional conformal radiation therapyProportion of patientsInvasive radical prostatectomyOpen surgical approachProstate cancerIntensity-modulated radiation therapyRadiation therapyDeprivation therapyConformal radiation therapyRadical prostatectomySurgical approachMedicare populationRetrospective claims-based analysisIncident prostate cancerClaims-based analysisManagement of patientsLarge clinical trialsLocalized prostate cancerTreatment of patientsExternal beam radiotherapyHealth care costsActive therapyInitial treatmentOptimal therapy